Abstract
A COMPARATIVE, TWO ARM, RANDOMIZED, DOUBLE BLIND, PARALLEL GROUP, MULTICENTRIC, NON-INFERIOR CLINICAL STUDY TO EVALUATE EFFICACY, SAFETY AND TOLERABILITY OF IGURATIMOD TABLETS 25 MG AS AN ADD ON THERAPY OVER METHOTREXATE TABLETS 15 MG VS. METHOTREXATE TAB

*Dr. Shailesh Singh, Dr. Karuna Ramteke, Khushwant Khatri and Pravin Hule

ABSTRACT

Background: This study was designed to evaluate the efficacy, safety and tolerability of Iguratimod Tablets 25 mg for the treatment of patients with active rheumatoid arthritis. The objectives of this study were percentage of patients meeting ACR20, ACR50, ACR70 response criteria, mean reduction in DAS28 and HAQ score. Method: This was randomized, double-blind, study conducted in nine centers across India. The study was conducted in male or female subjects of the age 18 to 65 years. A total of 243 subjects were randomized in study. The treatment period was 28 week with follow-up on week 4, 8, 12, 18 and week 24 from the start of treatment. Results: At the end of study, 100% patients achieved ACR20, 73.45% patients achieved ACR50 and 19.47% patients achieved ACR70 criteria in Iguratimod group vs. 97.39% patients achieved ACR20, 61.74% patients achieved ACR50 and 10.43% patients achieved ACR70 criteria in Methotrexate group. The mean change in DAS28 at the end of study was -2.22 vs -2.0 in Iguratimod and Methotrexate group respectively. The mean change in HAQ score at the end of study was -0.91 vs -0.77 in Iguratimod and Methotrexate group respectively. There were 61 clinical adverse events reported in 45 subjects. No adverse event led to SAE. Conclusion: The add on therapy of Iguratimod Tablets 25 mg to Methotrexate Tablets 15 mg is statistically equivalent in achieving the ACR20, ACR50 and ACR70 criteria and statistically superior to mean reduction in DAS28 and HAQ score as compared to Methotrexate Tablets 25 mg.

Keywords: .


[Full Text Article]

Login





Forgot Password  |  Register

Indexing

Best Paper Awards

European Journal of Biomedical and Pharmaceutical Sciences (EJBPS) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.

Best Article of current issue :

Dr. Dhrubo Jyoti Sen

Download Article : Click here

News & Updation

  • EJBPS: MAY ISSUE PUBLISHED

    MAY 2022 Issue has been successfully launched on 1 May 2022.

  • EJBPS New Impact Factor

    Its our Pleasure to Inform you that EJBPS Impact Factor has been increased from 5.467 to 6.044, due to high quality Publication at International Level.

  • Index Copernicus Value

    EJBPS Received Index Copernicus Value 77.3, due to High Quality Publication in EJBPS at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in EJBPS coming Issue.

     

UG/PG/Ph.D Research Publication

Research Scholar of UG/PG/Ph.D can Submit their Research Article/Review Article/Case Study/Short Communication for Publication in EJBPS

Downloads

Copyright From

Covering Letter

                        Author Instruction 
 

PLAGERLUM REPORT